Skip to main content
Erschienen in: Lasers in Medical Science 7/2019

04.03.2019 | Letter to the Editor

In response to the FDA warning about the use of photomedicine in gynecology

verfasst von: Juan José Escribano, Pablo González-Isaza, Konstantinos Tserotas, Stavros Athanasiou, Nicola Zerbinati, Gustavo Leibaschoff, Stefano Salvatore, Rafael Sánchez-Borrego

Erschienen in: Lasers in Medical Science | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

To alert patients and health care providers about the use of energy-based devices to perform a vaginal “rejuvenation,” cosmetic vaginal procedures, or nonsurgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function, the US Food and Drug Administration (FDA) has issued a warning about the effectiveness and safety of such devices. We agree with the FDA that certain devices (laser, radiofrequency, etc.) have been marketed inappropriately for uses that are outside of their cleared or approved intended uses. We want to position ourselves in the strict training of professionals so that the indications and techniques are used in the best possible way, knowing that, similar to any medical or surgical technique, the side effects can appear in the short and long term, and should be recognized and remedied.
Literatur
1.
Zurück zum Zitat FDA Warns Against Use of Energy-Based Devices to Perform Vaginal “Rejuvenation” or Vaginal Cosmetic Procedures: FDA safety communication. Date Issued: July 30, 2018 FDA Warns Against Use of Energy-Based Devices to Perform Vaginal “Rejuvenation” or Vaginal Cosmetic Procedures: FDA safety communication. Date Issued: July 30, 2018
2.
Zurück zum Zitat The American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and US Food and Drug Administration clearance: position statement. May 2016 The American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and US Food and Drug Administration clearance: position statement. May 2016
3.
Zurück zum Zitat Portman DJ, Gass ML (2014) Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med 11(12):2865–2872CrossRefPubMed Portman DJ, Gass ML (2014) Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med 11(12):2865–2872CrossRefPubMed
4.
Zurück zum Zitat Bachmann G, Santen RJ (2018) Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy). UpToDate Bachmann G, Santen RJ (2018) Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy). UpToDate
5.
Zurück zum Zitat Salvatore S, Athanasiou S, Candiani M (2015) The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27(6):504–508PubMed Salvatore S, Athanasiou S, Candiani M (2015) The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27(6):504–508PubMed
6.
Zurück zum Zitat González-Isaza P, Sánchez-Borrego R, Escribano JJ, Zerbinati N, Tserotas K, Leibaschoff G (2018 June) Letters To the editor. Menopause 25(6):710CrossRefPubMed González-Isaza P, Sánchez-Borrego R, Escribano JJ, Zerbinati N, Tserotas K, Leibaschoff G (2018 June) Letters To the editor. Menopause 25(6):710CrossRefPubMed
7.
Zurück zum Zitat Krychman M, Rowan CG, Allan BB, Durbin S, Yacoubian A, Wilkerson D (2018) Effect of single-session, cryogen-cooled monopolar radiofrequency therapy on sexual function in women with vaginal laxity: the VIVEVE I trial. J Women’s Health 27(3):297–304CrossRef Krychman M, Rowan CG, Allan BB, Durbin S, Yacoubian A, Wilkerson D (2018) Effect of single-session, cryogen-cooled monopolar radiofrequency therapy on sexual function in women with vaginal laxity: the VIVEVE I trial. J Women’s Health 27(3):297–304CrossRef
8.
Zurück zum Zitat Blaganje M, Šćepanović D, Žgur L, Verdenik I, Pajk F, Lukanović A (2018) Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 224:153–158CrossRefPubMed Blaganje M, Šćepanović D, Žgur L, Verdenik I, Pajk F, Lukanović A (2018) Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 224:153–158CrossRefPubMed
9.
Zurück zum Zitat Pitsouni E, Grigoriadis T, Falagas ME et al (2017) Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas 103:78CrossRefPubMed Pitsouni E, Grigoriadis T, Falagas ME et al (2017) Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas 103:78CrossRefPubMed
10.
Zurück zum Zitat Arunkalaivanan A, Kaur H, Onuma O (2017) Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J 28:681–685CrossRefPubMed Arunkalaivanan A, Kaur H, Onuma O (2017) Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J 28:681–685CrossRefPubMed
Metadaten
Titel
In response to the FDA warning about the use of photomedicine in gynecology
verfasst von
Juan José Escribano
Pablo González-Isaza
Konstantinos Tserotas
Stavros Athanasiou
Nicola Zerbinati
Gustavo Leibaschoff
Stefano Salvatore
Rafael Sánchez-Borrego
Publikationsdatum
04.03.2019
Verlag
Springer London
Erschienen in
Lasers in Medical Science / Ausgabe 7/2019
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-019-02744-1

Weitere Artikel der Ausgabe 7/2019

Lasers in Medical Science 7/2019 Zur Ausgabe